Abstract
Introduction
Prevention of inflammation as well as minimizing early and late effects of an inflammatory response are an important component in the therapy of many human and animal diseases and disorders. Non-steroidal anti-inflammatory drugs (NSAIDs) play an enormous role in the management of inflammatory diseases and as analgesics and antipyretics. The major mechanism of action of NSAIDs is through the inhibition of the synthesis of proinflammatory prostaglandin (PG), specifically PGE 2 via blocking cyclooxygenase (COX) at sites of inflammation [1] . There are two COX isoforms: COX-1 and COX-2. In the traditional view, COX-1 is constitutively expressed in most tissues and has important roles in tissue homeostasis, particularly in the stomach and kidneys as well as in blood clotting [1] , whereas COX-2 is a predominantly inducible enzyme, expressed at sites of inflammation, infection and cancer that generates prostanoids, which drive disease pathogenesis [2] . Therefore, it has been commonly thought that the antiinflammatory action of NSAIDs mainly arises from the inhibition of COX-2, whereas their unwanted side effects are largely attributed to the inhibition of COX-1. However, COX-2 is also constitutively expressed and plays a physiological role in many tissues and organs [3] , while COX-1 is also involved in inflammatory reactions [4] . On the basis of their inhibitory activity on COX-1 and COX-2, at least three major classes of NSAIDs can be distinguished: 1) preferential COX-1 inhibitors, 2) non-selective COX inhibitors, and 3) selective COX-2 inhibitors [5] .
NSAIDs are a principal group of drugs administered to alleviate symptoms of inflammation which occur in the course of various bacterial or viral infections in humans and animals. It is widely held that the administration of these medications does not significantly influence the immune response to infection, and therefore does not compromise the treatment of an infection. Although NSAIDs are popu-lar all across the world, their effect on T cells has not been as thoroughly investigated as it might have been expected. CD4 + and CD8 + T cells are key players in cell-mediated immune protection of the body, providing a highly efficient defence against viral and bacterial infection. IL-2 is a pleiotropic cytokine, which plays pivotal roles in orchestrating immune responses. This cytokine can act both in an autocrine and paracrine fashion by binding to IL-2R [6] . Three distinct receptor chains have been identified as components of IL-2R: α (IL-2α, CD25), β (IL-2β, CD122) and γ (IL-2γ, CD132) chains. IL-2R may exist in three functional forms: the monomeric low-affinity receptor (CD25 + CD122 -CD132 -), the dimeric intermediate-affinity receptor (CD25 -CD122 + CD132 + ), and the trimeric high affinity receptor (CD25 + CD122 + CD132 + ); however, only the two latter ones are functional receptor forms [7] . The dimeric intermediate-affinity receptor is expressed by naive and memory CD4 + and CD8 + T cells [6] . In turn, the trimeric high affinity receptor is expressed on recently activated T cells [7] . A critical point in the development of an immune response is the activation of T lymphocytes, which requires IL-2 binding to its high-affinity IL-2R for optimal signalling. Thus, the CD25 molecule is needed for the high affinity binding of IL-2 to effector cells and is potently induced after T cell activation. Perusal of the available literature has shown a shortage of research on the effect of NSAIDs on CD25 expression on CD4 + and CD8 + T cells during their activation. In our previous investigations [8] [9] [10] [11] , we evaluated the influence of meloxicam (a NSAID) on the expression of CD25 by bovine peripheral blood T cells, but our research only dealt with constitutive, and not with activation-induced, expression. These studies demonstrated that the drug significantly down-regulated CD25 expression on CD4 + , CD8
+ and WC1 + T cells, although the effect did not manifest itself very strongly. In turn, other investigators [12] found that ibuprofen and naproxen, but not indomethacin, piroxicam and sulindac, interfered with the binding of IL-2 to T cells and significantly inhibited the proliferative response of T cells to this cytokine. In the light of these findings, a hypothesis was put forth, suggesting that NSAIDs can inhibit CD25 expression during T cells activation, thus making these cells less responsive to IL-2. The current study has been dedicated to the verification of this hypothesis under in vitro conditions. There are certain implications found in the literature suggesting that differences between NSAIDs with respect to their affinity to COX may impinge on the effect of these drugs on CD25 expression [13] . Considering the above as well as the fact that various classes of NSADs distinguished with respect to their affinity to COX-1 and COX-2 are used in medicine, this research focused on the effects of a preferential COX-1 inhibitor (acetylsalicylic acid -ASA), non-selective COX inhibitor (ketoprofen -KET) and selective COX-2 inhibitor (robenacoxib -ROB) on the CD25 expression on mitogen-activated murine CD4 + and CD8 + T cells. However, CD25 molecule is not exclusively the marker of T cell activation because natural and induced Foxp3 (Forkhead Box P3 protein)-expressing CD25 + CD4
+ regulatory T cells (Treg cells) are well known in humans and mice [14] . In the case of activated effector T cells, the CD25 expression is inducible, i.e. it occurs transiently during the activation of these cells [7] , whereas Treg cells express this molecule constitutively [14] . 
Isolation of lymphocytes and culture conditions
Head and neck lymph nodes and axillary lymph nodes were removed and subjected to dounce homogenization. The resulting cell suspensions were filtered through 70 μm cell strainer (BD Biosciences, San Jose, USA) and washed (300 × g for 5 min. at 5°C; the same parameters were used for all cell-washing procedures) with complete medium CM; RPMI 1640, 10% FBS, 10 mM HEPES buffer, 10 mM nonessential amino acids, 10 mM sodium pyruvate and 10 U/ml penicillin/streptomycin (all from SigmaAldrich, Munich, Germany). Cells were adjusted to a final concentration of 2.5 × 10 6 cells/ml in CM and seeded in 24-well plates in 1 ml aliquots and incubated for 12 h in the absence (negative -NEG CON and positive controls -POS CON, i.e. non-stimulated and stimulated cells, respectively) or presence of ASA (Sigma-Aldrich) or KET [22] ) and in ten-fold lower concentrations. Subsequently, cells were activated (with the exception of NEG CON) with concanavalin A (Con A; 5 μg/ml; Sigma-Aldrich) for 6 h. Drugs were dissolved in dimethyl sulfoxide (DMSO) and adequate volume of the solvent was added to control wells; all wells contained the same amount of DMSO (0.1% [v/v] ). Each experiment included 6 wells of lymphocytes (obtained from individual mice) for each condition tested. All experiments were repeated independently two times, using 6 different animals for each experiment (overall n = 12). The plates were incubated at 37°C in an atmosphere of humidified incubator with 5% CO 2 and 95% air. 
Flow cytometry

Extracellular staining
Intracellular staining for Foxp3
Following surface staining, cells were washed, fixed, permeabilized (Mouse Foxp3 buffer set, BD Biosciences), and labeled with PE-conjugated rat anti-mouse Foxp3 mAb (clone MF23, IgG2b, BD Bioscience) as previously described [23] .
FACS acquisition and analysis
Flow cytometry analysis was performed using a FACSCanto II cytometer (BD Biosciences). The data were acquired by FACSDiva version 6.1.3 software (BD Biosciences) and analyzed by FlowJo software (Tree Star Inc., Stanford, USA). Unstained and single fluorochrome-stained samples were used to set fluorochrome compensation levels. Fluorescence minus one staining was used to confirm the gating strategy used to identify CD25-and Foxp3-expressing cells. Absolute cell counts of lymphocyte subsets (i.e. number of cells from a particular subpopulation per sample) were calculated using the dual platform method, i.e. the absolute cell count was determined by calculating the data obtained from a cell counting chamber (the total number of cells in the well) by the percentage of particular cell subsets (the data from flow cytometric immunophenotyping).
Statistical analysis
All data are presented as the mean ±SD. Student's unpaired t test was used to compare the results between ASAor KET-or ROB-treated (at either concentration) and POS CON cells and between NEG CON and POS CON cells. A p-value less than 0.05 was considered to be statistically significant. The data were graphed with Sigmaplot software (version 12, Systat Software, Inc., Chicago, USA). + T cells ( Fig. 2A') . These results prove that Con A induced expression of CD25 on CD25 -CD4 + T cell but had no effect on the expression of Foxp3 and, consequently, on the count of Foxp3 + and CD25 -CD4 + T cells per sample (A' and B'), which was obtained from lymphocytes cultured at cell density of 2.5 × 10 6 cells/ml. Results are the mean (±SD) of two independent experiments with six animals per experiment (n = 12). 
Results
Effect of NSAIDs
CD8
+ cells (Fig. 3B') . This was accompanied by a significant increase in the percentage of Foxp3 + cells within the CD25 + CD8 + cell subset (Fig. 4A) (Fig. 3) . However, it was found that the exposure to this drug caused a significant increase in the percentage of Foxp3-expressing cells within CD25
+ CD8 + T cell subset (Fig. 4A ). This was not accompanied by a statistically significant change in the absolute count of Foxp3 Fig. 3A') ; KET in the concentration of 10 -5 M, but not in the lower one, caused a decrease in the absolute count of CD25 -
+ T cells (Fig. 3B') . These effects were not accompanied by any considerable changes in the percentage of CD25-expressing CD8 + T cells (Figs. 3A  and B ). In addition, it was demonstrated that the exposure to KET 10 -5 M led to a significant increase in the percentage of Foxp3 + cells within CD25 + CD8 + T cell subset (Fig. 4A ), but had no influence on the absolute count of Foxp3 + CD25 + CD8 + T cells (Fig. 4A') . The drug in both concentrations tested caused a substantial reduction in the absolute count of Foxp3
+ T cells (Fig. 4B') . The exposure to ROB 10 -7 M lowered the percentage and absolute count of CD25 + CD8 + T cells (Figs. 3A and A' ), but had no effect on the absolute count of CD25 -CD8 + T cells (Fig. 3B' ). This drug, in both of the applied concentrations, increased the percentage of Foxp3 + cells (Fig. 4A ). This was not accompanied by a change in the absolute count of Foxp3 + CD25 + CD8 + T cells (Fig. 4A') , although it was found that the exposure of cells to ROB 10 -7 M resulted in a considerable decrease in the absolute count of Foxp3
+ T cells (Fig. 4B') .
Discussion
The main objective of this study has been to determine the effect of NSAIDs -depending on their selectivity to + T cells did not differ from the control. ROB had a significant influence on the assessed parameters but interestingly when it was applied in the lower concentration. The higher concentration of this drug had hardly any effect on the analyzed cells. [13] , who also demonstrated that a preferential COX-1 inhibitor (indomethacin) had no effect on the activation-induced CD25 expression on CD3
+ cells, whereas a selective COX-2 inhibitor (NS398) down-regulated it. Furthermore, our previous studies showed that meloxicam, a preferential COX-2 inhibitor, reduced constitutive CD25 expression on bovine CD4 + ,
CD8
+ and WC1 + T cells [8] [9] [10] [11] . Besides, it was demonstrated that non-preferential COX inhibitors (ibuprofen and naproxen) significantly inhibited the proliferative response of T cells to IL-2, while preferential COX-1 inhibitors (indomethacin and piroxicam) did not alter this response. These results are consistent with the ones discussed herein, because a CD25 molecule is needed for the high affinity binding of IL-2 to aTeff cells [7] . Moreover, the current results referred to in the cited literature suggest that the inhibition of COX-2, and not of COX-1, can lead to reduction in the activation-induced CD25 expression on T cells. Considering the mechanism of action of NSAIDs, such results and conclusions may appear paradoxical, because our earlier studies revealed that PGE 2 down-regulated activation-induced CD25 expression on bovine CD4 + , CD8
+ and WC1 + T cells [24] . Moreover, there are reports [25] [26] [27] indicating that PGE 2 down-regulated the CD25 expression on human T cells. When taking into consideration these results as well as the fact that NSAIDs reduce the synthesis of PGE 2 , it should be expected that these drugs would up-regulate the CD25 expression. Clearly, the effect of NSAIDs on CD25 expression is produced through some other mechanism. The current data implicate that ASA and KET have some potential to induce Foxp3 expression in CD8 + and CD4 + T cells, respectively, which may mean that they are capable of generating Treg cells. This suggestion is supported by results of other studies, where it was proven than KET induced Foxp3 expression in lymph node cells [28] , and ASA increased the relative levels of Foxp3 + CD25
+ cells among CD4 + cells in the periphery and thymus of mice [29] .
Conclusions
In conclusion, ASA, unlike KET and ROB, did not affect the activation-induced CD25 expression on CD4 + and CD8 + T cells, nor did it influence the count of CD4 + and CD8 + aTeff and Trest cells. Both KET and ROB caused some loss among CD8 + aTeff cells, in addition to which KET induced a loss among CD8 + Trest cells. Moreover, ROB, but not the other drugs, reduced the activation-induced CD25 expression on CD4 + T cells. This finding suggests that non-selective COX inhibitors and selective COX-2 inhibitors may weaken the effector T cell response by decreasing the count of aTeff cells. On the other hand, the above effect can be interpreted as an immunosuppressive action, although it can also be perceived as an anti-inflammatory action. Our results suggest that ASA and KET possess certain potential to induce Foxp3 expression in CD25 + CD8
+ and CD25 + CD4 + T cells, respectively. However, it should be underlined that all the changes observed in this experiment were very weakly expressed and therefore it is uncertain whether they have clinical importance, despite being statistically significant.
